OmniAb, Inc. is a clinical‐stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high‐throughput screening and bioinformatics, OmniAb aims to streamline the development of next‐generation biologics across a range of disease areas.
At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single‐cell screening capabilities. These technologies enable the rapid identification of diverse lead candidates, reducing timelines from target validation to preclinical development. OmniAb also provides downstream services such as antibody humanization, affinity maturation, and developability assessment, supporting clients through key decision points in the discovery process.
The company collaborates with pharmaceutical and biotechnology organizations worldwide, offering customized discovery programs and licensing arrangements. OmniAb’s partnerships span North America, Europe and Asia‐Pacific, reflecting its commitment to global drug research and development. Through these alliances, the company seeks to expand its pipeline and bring innovative antibody therapies to market more efficiently.
Headquartered in Vancouver, British Columbia, OmniAb maintains research operations in the United States and Europe. The organization went public on the Nasdaq in mid-2022 and is led by President and Chief Executive Officer Jef Miller. Under his leadership, OmniAb continues to invest in platform enhancements and strategic collaborations to address unmet medical needs through antibody‐based interventions.
AI Generated. May Contain Errors.
